• 1. de Perio, M. A., Tsevat, J., Roselle, G. A., Kralovic, S. M., & Eckman, M. H. (2009). Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Archives of internal medicine, 169(2), 179.
• 2. Dewan, P. K., Grinsdale, J., Liska, S., Wong, E., Fallstad, R., & Kawamura, L. M. (2006). Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infectious Diseases, 6(1), 47.
• 3. Sterling, T. R., Villarino, M. E., Borisov, A. S., Shang, N., Gordin, F., Bliven-Sizemore, E., ... & Chaisson, R. E. (2011). Three months of rifapentine and isoniazid for latent tuberculosis infection. New England Journal of Medicine,365(23), 2155-2166.
• 4. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bulletin World Health Organization. 60: 555-64. 1982
• 5. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States. MMWR Recomm Rep 2010;59:1–25.
• 6. Detjen, A. K., Keil, T., Roll, S., Hauer, B., Mauch, H., Wahn, U., & Magdorf, K. (2007). Interferon-γ release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clinical Infectious Diseases, 45(3), 322-328.
• 7. Palazzo, R., Spensieri, F., Massari, M., Fedele, G., Frasca, L., Carrara, S., ... & Ausiello, C. M. (2008). Use of whole-blood samples in in-house bulk and single-cell antigen-specific gamma interferon assays for surveillance of Mycobacterium tuberculosis infections. Clinical and vaccine immunology, 15(2), 327-337.
• 8. Aichelburg, M. C., Rieger, A., Breitenecker, F., Pfistershammer, K., Tittes, J., Eltz, S., ... & Kohrgruber, N. (2009). Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-1–infected individuals. Clinical Infectious Diseases, 48(7), 954-962.
• 9. Bartu, V., Havelkova, M., & Kopecka, E. (2008). QuantiFERON®-TB Gold in the diagnosis of active tuberculosis. Journal of International Medical Research,36(3), 434-437.
• 10. Chee, C. B., Gan, S. H., KhinMar, K. W., Barkham, T. M., Koh, C. K., Liang, S., & Wang, Y. T. (2008). Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. Journal of clinical microbiology, 46(6), 1935-1940.
• 11. Oxlade, O., Schwartzman, K., & Menzies, D. (2007). Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. The International Journal of Tuberculosis and Lung Disease, 11(1), 16-26.
• 12. Harada, N., Higuchi, K., Yoshiyama, T., Kawabe, Y., Fujita, A., Sasaki, Y., ... & Ishikawa, N. (2008). Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for< i> M. tuberculosis infection. Journal of Infection, 56(5), 348-353.
• 13. Ruhwald, M., Bodmer, T., Maier, C., Jepsen, M., Haaland, M. B., Eugen-Olsen, J., & Ravn, P. (2008). Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. European Respiratory Journal,32(6), 1607-1615.
• 14. Linas, B. P., Wong, A. Y., Freedberg, K. A., & Horsburgh Jr, C. R. (2011). Priorities for screening and treatment of latent tuberculosis infection in the United States. American journal of respiratory and critical care medicine,184(5), 590-601.
• 15. Berkel, G. M., Cobelens, F. G. J., De Vries, G., Draayer-Jansen, I. W. E., & Borgdorff, M. W. (2005). Tuberculin skin test: estimation of positive and negative predictive values from routine data. The International Journal of Tuberculosis and Lung Disease, 9(3), 310-316.
• 16. Herrera, V., Perry, S., Parsonnet, J., & Banaei, N. (2011). Clinical application and limitations of interferon-γ release assays for the diagnosis of latent tuberculosis infection. Clinical infectious diseases, 52(8), 1031-1037.
• 17. LoBue, P. A., & Moser, K. S. (2003). Use of isoniazid for latent tuberculosis infection in a public health clinic. American Journal of Respiratory and Critical Care Medicine, 168(4), 443-447.
• 18. Rivest, P., Street, M. C., & Allard, R. (2013). Completion rates of treatment for latent tuberculosis infection in quebec, Canada from 2006 to 2010. Canadian Journal of Public Health, 104(3).